These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 32150821)
1. Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting. Baldin AV; Savvateeva LV; Bazhin AV; Zamyatnin AA Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32150821 [TBL] [Abstract][Full Text] [Related]
2. Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma. Fedorova L; Mudry P; Pilatova K; Selingerova I; Merhautova J; Rehak Z; Valik D; Hlavackova E; Cerna D; Faberova L; Mazanek P; Pavelka Z; Demlova R; Sterba J; Zdrazilova-Dubska L Front Oncol; 2019; 9():1169. PubMed ID: 31799177 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic dendritic cell-based cancer vaccines: the state of the art. Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347 [TBL] [Abstract][Full Text] [Related]
4. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. Ragde H; Cavanagh WA; Tjoa BA J Urol; 2004 Dec; 172(6 Pt 2):2532-8. PubMed ID: 15538202 [TBL] [Abstract][Full Text] [Related]
12. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma. Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based vaccine efficacy: aiming for hot spots. Pizzurro GA; Barrio MM Front Immunol; 2015; 6():91. PubMed ID: 25784913 [TBL] [Abstract][Full Text] [Related]
14. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Hájek R; Butch AW Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654 [TBL] [Abstract][Full Text] [Related]
17. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Tacken PJ; de Vries IJ; Torensma R; Figdor CG Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer? Chen W; Rains N; Young D; Stubbs RS J Gastroenterol Hepatol; 2000 Jul; 15(7):698-705. PubMed ID: 10937673 [TBL] [Abstract][Full Text] [Related]
19. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Garg AD; Coulie PG; Van den Eynde BJ; Agostinis P Trends Immunol; 2017 Aug; 38(8):577-593. PubMed ID: 28610825 [TBL] [Abstract][Full Text] [Related]
20. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]